News | Cardiovascular Clinical Studies | May 14, 2018

Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs

Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018

May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hospitalized with endocarditis has increased dramatically over the last decade in a pattern that mirrors the increase in mixed drug use. The nearly decade-long retrospective study analyzed patients in the epicenter of the opioid epidemic — West Virginia. Findings showed a trend between the significant increase in patients hospitalized with endocarditis from mixed drug abuse and the substantial cost it has on state and federal programs. The study was presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions.

The rise of opioid abuse is a growing health crisis in the United States, particularly in areas hardest hit by the economic downturn, with an average of 115 Americans dying every day from drug overdoses (NIDA). One of the most challenging and costly complications of the intravenous (IV) drug epidemic is endocarditis, a rare, life-threatening bacterial valve infection that can destroy heart valves and spread throughout the body. Endocarditis is often associated with heart defects or abnormal valves, but can also be formed by using unsanitary needles to inject drugs. This causes bacteria from the needle to be released directly into the bloodstream. Endocarditis is a hard to treat condition and often ends in death. According to the Centers for Disease Control (CDC), addicts with endocarditis are 10 times more likely than other patients to die or require a second surgery months after initially leaving the hospital.

The study systematically analyzed all patients who were admitted during a nine-year period with associated drug abuse and endocarditis, utilizing International Classification of Disease (ICD) codes. Patients involved in the study had been handling cocaine, OxyContin, Demerol, Percocet and other opioids in large doses, likely causing immune system compromise further increasing their risk for valve infection from bacteria repeatedly introduced into the bloodstream during drug injection. A time series model was used to investigate the effect of drug use on the incidence of endocarditis and estimate cost based on charges.

During the study period, a total of 462 patients were hospitalized with infective endocarditis and concomitant explicit drug use. Infective endocarditis cases increased from 26 cases in 2008 to 66 cases in 2015. Most of the patient cases were uninsured (10.4 percent) or underinsured by federal and/or state programs (10.6 percent and 56.2 percent respectively). Throughout the study period, $17.3 million was billed by the hospital, and the total reimbursement was only $3.8 million. In 2015 alone, the hospital lost $3.5 million to care for these patients. These staggering increases in costs to West Virginia and the hospital come at a time of regional economic uncertainty and contracting hospital reimbursement.

“Endocarditis is a serious, hard to treat condition that significantly increases one’s risk of death,” said lead author Mark Bates, M.D. and director of cardiovascular research advancement at Charleston Area Medical Center (CAMC). “We are working as a team to help find solutions for communities to combat the spread of pandemics and increase awareness in our cities about the dangers of opioid use and the life-threatening condition of endocarditis.”

The authors note an interest to further analyze the benefits of intensive preventive measures through heat mapping, such as selecting communities for needle exchanges, creating various support groups, and educating users on the dangers of IV drug use.

Complete listing of SCAI 2018 late-breaking trials with links to articles.

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init